Moving into GMP – Turning process into product
The complex journey of bringing a biologic to market – part 4 The transition into GMP manufacturing marks a defining moment in the development of a biologic drug. After extensive ...
Janet Hoogstraate, the CEO of NorthX Biologics, recently appeared in an episode of Q-podden, a podcast on manufacturing, quality and corporate culture in life science.
Janet discusses the latest trends and innovations in the biotech industry, offering her unique perspective and expertise. It’s definitely worth a listen for anyone interested in the field!
Click the link below to listen (in Swedish):
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The complex journey of bringing a biologic to market – part 4 The transition into GMP manufacturing marks a defining moment in the development of a biologic drug. After extensive ...
Abstract Negar Ordouzadeh, Rossella Crescitelli, Agnes Zimmer, Petra Tjärnlund, Cecilia Lässer, Jan Lötvall, Kyong-Su Park Bacterial vesicles have emerged as therapeutic drug candidates to treat a wide range of diseases, including cancer. However, critical concerns remain ...
The complex journey of bringing a biologic to market – part 3 It is a critical shift for companies when transitioning from early development to clinical production, where you transfer ...